Compounds > ro 32-3555
Page last updated: 2024-09-05

ro 32-3555 and Adjuvant Arthritis

ro 32-3555 has been researched along with Adjuvant Arthritis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Close, DR1
Bishop, J; Bottomley, KM; Bradshaw, D; Brewster, M; Broadhurst, MJ; Brown, PA; Budd, JM; Elliott, L; Greenham, AK; Johnson, WH; Lewis, EJ; Nixon, JS; Rose, F; Sutton, B; Wilson, K1

Reviews

1 review(s) available for ro 32-3555 and Adjuvant Arthritis

ArticleYear
Matrix metalloproteinase inhibitors in rheumatic diseases.
    Annals of the rheumatic diseases, 2001, Volume: 60 Suppl 3

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Imidazoles; Matrix Metalloproteinase Inhibitors; Mice; Randomized Controlled Trials as Topic; Rheumatic Diseases; Treatment Outcome

2001

Other Studies

1 other study(ies) available for ro 32-3555 and Adjuvant Arthritis

ArticleYear
Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
    British journal of pharmacology, 1997, Volume: 121, Issue:3

    Topics: Administration, Oral; Animals; Arthritis, Experimental; Cartilage; Cattle; Humans; Imidazoles; Male; Matrix Metalloproteinase Inhibitors; Protease Inhibitors; Rats; Rats, Sprague-Dawley

1997